Patents by Inventor Pascal Grenier

Pascal Grenier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200049591
    Abstract: A pylon for supporting an aircraft turbomachine, in particular for a test bench, the pylon having a generally elongated shape along an axis and including, at a first longitudinal end, first members for fixing to a turbomachine and, at a second longitudinal end, second members for fixing to a base plate, the pylon being traversed by at least one fluid pipe including a first end for connecting to the turbomachine and a second end for connecting to a fluid supply circuit, wherein the at least one pipe includes a movable portion movable in translation along the axis so as to be able to adjust the position along the axis of the first connecting end relative to the first longitudinal end. It also concerns a method of mounting an aircraft turbomachine on such a pylon.
    Type: Application
    Filed: August 7, 2019
    Publication date: February 13, 2020
    Inventors: Jacky Raphael Michel DERENES, Michael Daniel Joel BERTIN, Etienne Romain Pascal GRENIER
  • Patent number: 10076500
    Abstract: An elongate dosage form of generally cylindrical shape having two opposing ends, the dosage form being buoyant in gastric fluid, wherein the dosage form is weight biased such that one end is heavier than the other end. The dosage form is adapted to float on gastric fluid with its long axis substantially perpendicular to the surface of the fluid with its heavier end pointing generally downwards and into the fluid.
    Type: Grant
    Filed: March 17, 2016
    Date of Patent: September 18, 2018
    Assignee: Jagotec AG
    Inventors: Pascal Grenier, Alain Nhamias, Guy Vergnault
  • Patent number: 9884021
    Abstract: A tablet comprising a core containing an active agent, and a coating, the core being disposed within the coating such that the coating has a thickness about a longitudinal axis (X-Y) of about 4.85 to 4.95 mm. The position of the core within the coating dictating that the active agent is released rapidly after a lag time during which time no active agent is released.
    Type: Grant
    Filed: October 7, 2015
    Date of Patent: February 6, 2018
    Assignee: Jagotec AG
    Inventors: Guy Vergnault, Pascal Grenier, Christophe Dragan
  • Patent number: 9622980
    Abstract: The invention provides controlled release oral dosage formulations containing one or more active agents, and methods of using same. In one aspect, the formulation is in the form of a trilayer tablet containing a core or central layer and one or more barrier layers. The core may contain one or more enteric materials or polymeric materials which modulates the release of the active agent.
    Type: Grant
    Filed: July 10, 2015
    Date of Patent: April 18, 2017
    Assignee: Jagotec AG
    Inventors: Pascal Grenier, Alain Nhamias, Guy Vergnault
  • Publication number: 20160263045
    Abstract: An elongate dosage form of generally cylindrical shape having two opposing ends, the dosage form being buoyant in gastric fluid, wherein the dosage form is weight biased such that one end is heavier than the other end. The dosage form is adapted to float on gastric fluid with its long axis substantially perpendicular to the surface of the fluid with its heavier end pointing generally downwards and into the fluid.
    Type: Application
    Filed: March 17, 2016
    Publication date: September 15, 2016
    Inventors: Pascal Grenier, Alain Nhamias, Guy Vergnault
  • Publication number: 20160256396
    Abstract: A tablet comprising a core containing an active agent, and a coating, the core being disposed within the coating such that the coating has a thickness about a longitudinal axis (X-Y) of about 4.85 to 4.95 mm. The position of the core within the coating dictating that the active agent is released rapidly after a lag time during which time no active agent is released.
    Type: Application
    Filed: October 7, 2015
    Publication date: September 8, 2016
    Inventors: Guy Vergnault, Pascal Grenier, Christophe Dragan
  • Patent number: 9314430
    Abstract: An elongate dosage form of generally cylindrical shape having two opposing ends, the dosage form being buoyant in. gastric fluid, wherein the dosage form is weight biased such that. one end is heavier than the ether end. The dosage form is adapted to float on gastric fluid with its long axis substantially perpendicular to the surface of the: fluid with its heavier end pointing: generally; downwards and into the fluid.
    Type: Grant
    Filed: July 4, 2011
    Date of Patent: April 19, 2016
    Assignee: Jagotec AG
    Inventors: Pascal Grenier, Alain Nhamias, Guy Vergnault
  • Publication number: 20160008288
    Abstract: The invention provides controlled release oral dosage formulations containing one or more active agents, and methods of using same. In one aspect, the formulation is in the form of a trilayer tablet containing a core or central layer and one or more barrier layers. The core may contain one or more enteric materials or polymeric materials which modulates the release of the active agent.
    Type: Application
    Filed: July 10, 2015
    Publication date: January 14, 2016
    Inventors: Pascal Grenier, Alain Nhamias, Guy Vergnault
  • Patent number: 9186332
    Abstract: A tablet comprising a core containing an active agent, and a coating, the core being disposed within the coating such that the coating has a thickness about a longitudinal axis (X-Y) of about 4.85 to 4.95 mm. The position of the core within the coating dictating that the active agent is released rapidly after a lag time during which time no active agent is released.
    Type: Grant
    Filed: December 13, 2012
    Date of Patent: November 17, 2015
    Assignee: Jagotec AG
    Inventors: Guy Vergnault, Pascal Grenier, Christophe Dragan
  • Patent number: 9101544
    Abstract: Controlled release oral dosage formulations containing calcium channel blockers, and methods of use thereof, are provided for the once-a-day treatment of cardiovascular disorders, such as hypertension, angina, and cardiac arrhythmia. The active agent is preferably a dihydropyridine calcium channel blocker, such as nisoldipine. The formulation provides an increase in the bioavailability of the calcium channel blocker as compared to the bioavailability of the calcium channel blocker in other drug delivery formulations known in the art. In one embodiment, the formulation provides an increase in the bioavailability of the calcium channel blocker, nisoldipine, as compared to the same dose of nisoldipine in the coat-core version of the drug (SULARĀ®). The formulation can be in the form of a trilayer tablet containing a core or central layer and one or more barrier layers.
    Type: Grant
    Filed: August 29, 2007
    Date of Patent: August 11, 2015
    Assignee: Jagotec AG
    Inventors: Pascal Grenier, Alain Nhamias, Guy Vergnault
  • Patent number: 9040085
    Abstract: A tablet comprising a core containing an active agent, and a coating, the core being disposed within the coating such that the coating has a thickness about a longitudinal axis (X-Y) of about 4.85 to 4.95 mm. The position of the core within the coating dictating that the active agent is released rapidly after a lag time during which time no active agent is released.
    Type: Grant
    Filed: July 11, 2014
    Date of Patent: May 26, 2015
    Assignee: Jagotec AG
    Inventors: Guy Vergnault, Pascal Grenier, Christophe Dragan
  • Publication number: 20150133416
    Abstract: Pharmaceutical composition comprising abiraterone acetate, which exhibits a reduced food effect and improved bioavailability.
    Type: Application
    Filed: May 3, 2013
    Publication date: May 14, 2015
    Inventors: Pascal Grenier, Guy Vergnault
  • Patent number: 8980363
    Abstract: The present invention provides a method and apparatus for positioning the core of the compression coated tablet in manufacturing techniques for the production of such tablets.
    Type: Grant
    Filed: February 15, 2008
    Date of Patent: March 17, 2015
    Assignee: Jagotec AG
    Inventors: Pascal Grenier, Guy Vergnault
  • Patent number: 8927608
    Abstract: A formulation comprising dexamphetamine and lys-dexamphetamine useful in the treatment of ADHD or fatigue.
    Type: Grant
    Filed: February 16, 2011
    Date of Patent: January 6, 2015
    Assignee: Jagotec AG
    Inventors: Guy Vergnault, Pascal Grenier
  • Patent number: 8927028
    Abstract: A dosage form exhibiting delayed transit time through the GI tract. The dosage form comprises a plurality of buoyant particles, each comprising an inner drug-containing core, an intermediate layer surrounding said core and a release rate-controlling outer coating.
    Type: Grant
    Filed: December 15, 2005
    Date of Patent: January 6, 2015
    Assignee: Jagotec AG
    Inventors: Pascal Grenier, Julien Taillemite, Severine Serreau, Alain Nhamias
  • Publication number: 20140328912
    Abstract: A tablet comprising a core containing an active agent, and a coating, the core being disposed within the coating such that the coating has a thickness about a longitudinal axis (X-Y) of about 4.85 to 4.95 mm. The position of the core within the coating dictating that the active agent is released rapidly after a lag time during which time no active agent is released.
    Type: Application
    Filed: July 11, 2014
    Publication date: November 6, 2014
    Inventors: Guy Vergnault, Pascal Grenier, Christophe Dragan
  • Publication number: 20140255499
    Abstract: A method of forming fine particles of a drug substance using a piston-gap high pressure homogeniser.
    Type: Application
    Filed: October 5, 2012
    Publication date: September 11, 2014
    Inventors: Guy Vergnault, Alain Nhamias, Pascal Grenier
  • Publication number: 20140243296
    Abstract: A treatment regimen and dosage form comprising ritonavir and darunavir and their use in the treatment of HIV infection.
    Type: Application
    Filed: October 5, 2012
    Publication date: August 28, 2014
    Applicant: JAGOTEC AG
    Inventors: Pascal Grenier, Guy Vergnault, Patricia Ibarra
  • Patent number: 8663693
    Abstract: Nanoparticles and nanoparticle formulations or suspensions are provided which comprise a fibrate and vitamin E TPGS. The nanoparticles may have a mean diameter, measured by photon correlation spectroscopy, in the range of from about 100 nm to about 900 nm. Pharmaceutical formulations and uses of such compositions are also provided.
    Type: Grant
    Filed: August 9, 2002
    Date of Patent: March 4, 2014
    Assignee: Jagotec AG
    Inventors: Pascal Grenier, Guy Vergnault, Alain Nhamias
  • Patent number: 8460706
    Abstract: An oral dosage form comprising a pharmaceutical tablet of one or more layers, one of which carries a biologically active substance; the formulation of said tablet includes different percentages of hydrophilic and lipophilic polymeric materials, and adjuvant substances. The tablets of the present invention show a release rate which is independent from the amounts of active substance present in the tablet.
    Type: Grant
    Filed: February 7, 2011
    Date of Patent: June 11, 2013
    Assignee: Jagotec AG
    Inventors: Guy Vergnault, Pascal Grenier, Lauretta Maggi, Ubaldo Conte